

Q2 INVESTOR WEBINAR

- **PYC will hold an investor webinar on Thursday 9 May 2024 at 9:00am AWST/11:00am AEST**

PERTH, Australia and SAN FRANCISCO, California – 1 May 2024

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) will hold an investor webinar to update shareholders on progress made in 2024 on Thursday 9 May 2024 at 9:00am AWST (11:00am AEST).

Shareholders are invited to attend in person at the McCusker Auditorium at the Harry Perkins Institute North Campus in Nedlands, Western Australia or register for the online link to the webinar below:

https://us02web.zoom.us/webinar/register/WN_Wn1FOCK_SWOS123Buf-EdQ

After registering, you will receive a confirmation email containing information about joining the webinar.

This announcement was approved for release by the CEO of PYC Therapeutics Limited.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood (Retinitis Pigmentosa type 11) into human trials. The Company is progressing a second drug program targeting a blinding eye disease (Autosomal Dominant Optic Atrophy) and a third program targeting Polycystic Kidney Disease which are anticipated to commence human trials in mid-2024 and early 2025 respectively.

For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank <https://doi.org/10.1101/2020.11.02.20222232>

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com